Kotowski Ulana, Kadletz Lorenz, Schneider Sven, Oberndorfer Felicitas, Erovic Boban M, Grasl Matthaeus Ch, Lill Claudia, Heiduschka Gregor
Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Department of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Pathol Oncol Res. 2019 Apr;25(2):585-591. doi: 10.1007/s12253-018-0475-8. Epub 2018 Oct 29.
Engulfment and cell motility 3 protein (ELMO3) is a protein that is involved in cell migration and promotes the remodeling of the cytoskeleton. Moreover, it is described as a prognostic marker in several cancers. The aim of this study was to evaluate ELMO3 expression in patients with minor salivary gland carcinoma. The expression of ELMO3 was examined by immunohistochemistry. The intensity of staining was evaluated and data was correlated to clinical outcome. Forty-six patients with complete clinical data were included into statistical analysis. ELMO3 expression was observed in 85% of the cases. High staining intensity of ELMO3 correlated with a significantly worse disease free survival (p = .0495) and a higher recurrence rate (p = .0071). In conclusion, it is still difficult to predict the clinical outcome of patients with minor salivary gland carcinoma. Evaluation of ELMO3 might serve as a clinical prognostic marker in future.
吞噬与细胞运动3蛋白(ELMO3)是一种参与细胞迁移并促进细胞骨架重塑的蛋白质。此外,它在几种癌症中被描述为一种预后标志物。本研究的目的是评估小涎腺癌患者中ELMO3的表达情况。通过免疫组织化学检测ELMO3的表达。评估染色强度,并将数据与临床结果相关联。46例具有完整临床数据的患者纳入统计分析。85%的病例中观察到ELMO3表达。ELMO3的高染色强度与无病生存率显著降低(p = 0.0495)和复发率较高(p = 0.0071)相关。总之,预测小涎腺癌患者的临床结果仍然困难。ELMO3评估可能在未来作为一种临床预后标志物。